Psyence Biomedical Ltd.
PBM
$3.48
-$0.08-2.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -153.67% | -153.67% | -167.31% | -167.31% | 96.07% |
| Total Depreciation and Amortization | 8.33% | 8.33% | 44.44% | 44.44% | 1,100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -16.52% | -16.52% | 94.72% | 94.72% | -99.39% |
| Change in Net Operating Assets | -148.76% | -148.76% | 11.40% | 11.40% | 53.34% |
| Cash from Operations | -175.60% | -175.60% | -33.87% | -33.87% | -63.45% |
| Capital Expenditure | 100.00% | 100.00% | 96.88% | 96.88% | 41.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7,712.50% | -7,712.50% | -- | -- | -- |
| Cash from Investing | -5,002.04% | -5,002.04% | -62,578.13% | -62,578.13% | -68.97% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 47.34% | 47.34% | 309.82% | 309.82% | 3,347.09% |
| Cash from Financing | 7.43% | 7.43% | 159.24% | 159.24% | 331.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -92.99% | -92.99% | -15.39% | -15.39% | 3,188.42% |